echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Johnson & Johnson's Ebola vaccine program safely induces strong immune responses in healthy and HIV adults

    Johnson & Johnson's Ebola vaccine program safely induces strong immune responses in healthy and HIV adults

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, data from a study published in the journal PLOS Medicine in the United States showed that Johnson & Johnson (JNJ)'s Ebola vaccine program (2-dose immunization)-Zabdeno® (Ad26.


    Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) received marketing authorization from the European Commission (EC) in July 2020, and was prequalified by the World Health Organization (WHO) in April 2021


    Since the outbreak of the West Africa epidemic in 2014, with the power of global public-private cooperation, Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) obtained regulatory approval in less than 6 years


    The data published in the journal PLOS Medicine come from the second phase of the EBL2002 study


    Since the Ebola virus was discovered in 1976, more than 30 outbreaks have been announced, the most serious of which has occurred in Africa in the past seven years


    Johnson & Johnson responded to the recent Ebola epidemic by providing vaccine programs to governments and the World Health Organization (WHO)


    Note: The original text has been deleted

    Original source: Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.